Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.
Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.
Omeros received approximately $126 million in cash at closing. In addition, Omeros retains and is entitled to collect the full amount of its accounts receivable outstanding as of today’s closing.
The GMP Facility for commercial manufacturing CAR-T Cell therapy and R&D Center for further pipeline development are constituting the 17,325 square-meter site of CAR-T Center.
This exciting product line will add new dimensions to Neoss existing Bone Regeneration offering, providing an enhanced offering of Bone materials and membranes.
USMI & JCRI have developed a Humidified Electrical Reactive Oxygen System (The Canady Helios™ Cold Plasma HERO™ System) which generates an ionized cold plasma mixed with the Air/O2 from oxygen sources such as hospital ventilators, CPAPs (Continuous Positive Airway Pressure), BIPAPs (Bilevel Positive Airway Pressure) or O2 face masks.
Fast and accurate testing labs at international terminals offer a new solution, as airports continue to be a focal point in the global spread of COVID-19.
Medtecs notes the world has been hit again by the resurgence in confirmed COVID-19 cases brought about by the highly contagious Delta variant. The number of cases worldwide has surpassed the 200 million mark, with a large number of children now being included in the daily tally, straining pediatric resources and healthcare systems.
According to medical experts, children under the age of 12 who are not yet eligible for vaccination are at high risk for infection by the Delta variant....
This integration unlocks new antibody discovery workflows like performing structural analysis of proteins of interest and annotating important liability characteristics to select antibody candidates with good developability properties.
